KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals (NASDAQ: KALV) has granted inducement stock options to ten newly-hired employees. The aggregate grant consists of 87,000 shares of KalVista common stock, issued on April 1, 2025.
The options' exercise price matches KalVista's common stock closing price on the grant date. The vesting schedule includes 25% after one year, with the remaining vesting monthly over three years, contingent on continued employment. The options have a 10-year term and fall under KalVista's Inducement Equity Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4).
KalVista Pharmaceuticals (NASDAQ: KALV) ha concesso opzioni di acquisto azionario di incentivazione a dieci nuovi dipendenti. L'assegnazione totale consiste in 87.000 azioni di azioni ordinarie di KalVista, emesse il 1° aprile 2025.
Il prezzo di esercizio delle opzioni corrisponde al prezzo di chiusura delle azioni ordinarie di KalVista nella data di assegnazione. Il piano di maturazione prevede il 25% dopo un anno, con il restante che matura mensilmente per tre anni, a condizione di continuare l'impiego. Le opzioni hanno un termine di 10 anni e rientrano nel Piano di Incentivazione Azionaria di Inducement di KalVista, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
KalVista Pharmaceuticals (NASDAQ: KALV) ha otorgado opciones de acciones de inducción a diez nuevos empleados. La concesión total consiste en 87,000 acciones de acciones ordinarias de KalVista, emitidas el 1 de abril de 2025.
El precio de ejercicio de las opciones coincide con el precio de cierre de las acciones ordinarias de KalVista en la fecha de concesión. El cronograma de adquisición incluye el 25% después de un año, con el restante adquiriéndose mensualmente durante tres años, condicionado a la continuidad del empleo. Las opciones tienen un plazo de 10 años y están bajo el Plan de Incentivos de Capital de Inducción de KalVista, cumpliendo con la Regla de Cotización de Nasdaq 5635(c)(4).
칼비스타 제약 (NASDAQ: KALV)는 새로 채용된 10명의 직원에게 유인 주식 옵션을 부여했습니다. 총 부여된 주식은 87,000주의 칼비스타 보통주로, 2025년 4월 1일에 발행되었습니다.
옵션의 행사 가격은 부여일의 칼비스타 보통주 종가와 일치합니다. 취득 일정은 1년 후 25%가 발생하며, 나머지는 3년 동안 매월 발생하며, 계속 고용되는 조건입니다. 이 옵션은 10년의 기간을 가지며, 칼비스타의 유인 주식 인센티브 계획에 따라 Nasdaq 상장 규칙 5635(c)(4)를 준수합니다.
KalVista Pharmaceuticals (NASDAQ: KALV) a accordé des options d'achat d'actions d'incitation à dix nouveaux employés. La subvention totale se compose de 87 000 actions d'actions ordinaires de KalVista, émises le 1er avril 2025.
Le prix d'exercice des options correspond au prix de clôture des actions ordinaires de KalVista à la date de la subvention. Le calendrier d'acquisition prévoit 25 % après un an, le reste étant acquis mensuellement sur trois ans, sous réserve de la continuité de l'emploi. Les options ont une durée de 10 ans et relèvent du Plan d'Incitation en Actions de KalVista, conformément à la Règle de Cotation Nasdaq 5635(c)(4).
KalVista Pharmaceuticals (NASDAQ: KALV) hat zehn neu eingestellten Mitarbeitern Anreiz-Aktienoptionen gewährt. Die Gesamtheit der Gewährung umfasst 87.000 Aktien von KalVista-Stammaktien, die am 1. April 2025 ausgegeben wurden.
Der Ausübungspreis der Optionen entspricht dem Schlusskurs der KalVista-Stammaktien am Tag der Gewährung. Der Vesting-Zeitplan sieht vor, dass 25% nach einem Jahr fällig werden, während der Rest über drei Jahre monatlich fällig wird, abhängig von einer fortgesetzten Beschäftigung. Die Optionen haben eine Laufzeit von 10 Jahren und fallen unter KalVistas Anreiz-Aktienplan, der den Nasdaq-Listing-Regeln 5635(c)(4) entspricht.
- None.
- None.
One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista’s Inducement Equity Incentive Plan and a stock option agreement covering the grant.
The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our lead investigational product is sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE). Sebetralstat is under regulatory review by the
For more information about KalVista, please visit www.kalvista.com or follow on social media at @KalVista and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402590873/en/
KalVista Pharmaceuticals, Inc.
Investors:
Ryan Baker
Head, Investor Relations
(617) 771-5001
ryan.baker@kalvista.com
Media:
Molly Cameron
Director, Corporate Communications
(857) 356-0164
molly.cameron@kalvista.com
Source: KalVista Pharmaceuticals, Inc.
FAQ
How many shares were granted in KalVista's (KALV) April 2025 inducement options?
What is the vesting schedule for KALV's April 2025 inducement stock options?
What is the exercise price for KalVista's (KALV) April 2025 inducement options?
How long is the term of KALV's April 2025 inducement stock options?
